Market News AIOpen the app

Jefferies Maintains Hold Rating on Novartis

OpinionRead the original at finanzen.ch
Neutral

Higher sales forecasts for 3 drugs support growth and reduce risk. But unanswered questions about other products leave Novartis's longer-term prospects balanced.

NVS · Novartis

AI read · Neutral

The AI's read

Higher expected sales for Kesimpta, Scemblix, and Lewvio support growth and reduce risk. But Jefferies says the longer-term picture still depends on products with unanswered questions. Those points do not show a clear change in Novartis's prospects.

Get alerts for NVS

Follow Novartis (NVS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NVS
Free on the App Store and Google Play, or on the web.